output
20212025
most citedOn model-based time trend adjustments in platform trials with non-concurrent controls

64 citations

researchers with a paper here

Counting papers with at most 25 authors, so collaboration author lists do not stand in for the people here.

collaborating institutions

6 papers

stat.ME2025

Inverse Probability Weighting for Recurrent Event Models

Jiren Sun, Tobias Mutze, Richard Cook +1

Recurrent events are common and important clinical trial endpoints in many disease areas, e.g., cardiovascular hospitalizations in heart failure, relapses in multiple sclerosis, or…

stat.AP2025★ 3 cited

Using Individualized Treatment Effects to Assess Treatment Effect Heterogeneity

Konstantinos Sechidis, Cong Zhang, Sophie Sun +3

Assessing treatment effect heterogeneity (TEH) in clinical trials is crucial, as it provides insights into the variability of treatment responses among patients, influencing import…

stat.ME2024★ 1 cited

Randomization-based Inference for MCP-Mod

Lukas Pin, Oleksandr Sverdlov, Frank Bretz +1

Dose selection is critical in pharmaceutical drug development, as it directly impacts therapeutic efficacy and patient safety of a drug. The Generalized Multiple Comparison Procedu…

stat.AP2024★ 3 cited

WATCH: A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors

Konstantinos Sechidis, Sophie Sun, Yao Chen +8

This paper proposes a Workflow for Assessing Treatment effeCt Heterogeneity (WATCH) in clinical drug development targeted at clinical trial sponsors. WATCH is designed to address t…

stat.ME2021★ 64 cited

On model-based time trend adjustments in platform trials with non-concurrent controls

Marta Bofill Roig, Pavla Krotka, Carl-Fredrik Burman +9

Platform trials can evaluate the efficacy of several treatments compared to a control. The number of treatments is not fixed, as arms may be added or removed as the trial progresse…

stat.AP2021★ 1 cited

Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials

Elias Laurin Meyer, Peter Mesenbrink, Cornelia Dunger-Baldauf +3

Platform trials have become increasingly popular for drug development programs, attracting interest from statisticians, clinicians and regulatory agencies. Many statistical questio…